Why Denali Therapeutics Stock Is Back in Focus

Denali Therapeutics (DNLI) is drawing fresh attention after reporting a wider net loss for the fourth quarter and full year, along with a new common stock shelf registration that signals possible future share issuance.

At a share price of US$21.18, Denali’s short term momentum has been mixed, with a 4.9% 7 day share price return alongside a 16.63% 90 day share price return and a 30.18% year to date share price return. The 1 year total shareholder return of 27.9% contrasts with a weaker 3 year and 5 year total shareholder return, as investors react to wider losses, potential dilution from the new shelf registration and progress across its Hunter syndrome and broader neurodegenerative pipeline.

If this earnings update has you reassessing biotech risk and reward, it could be a good moment to scan our screener of 27 healthcare AI stocks as potential next ideas.

With Denali posting a full year net loss of US$512.54 million and putting a US$200.73 million common stock shelf in place, the key question now is simple: is there real upside left here or is the market already pricing in future growth?

Preferred Price to Book of 3.3x: Is It Justified?

On a P/B of 3.3x at a share price of $21.18, Denali screens as good value against its own estimated fair value, yet a bit expensive versus the wider US biotech group.

The P/B ratio compares the market value of the company to its net assets on the balance sheet. This can be a useful yardstick for pre-profit biopharma names where earnings are not yet meaningful. For Denali, this metric sits at 3.3x, which our checks flag as good value relative to its own fundamentals and discounted cash flow profile.

That picture changes once you line it up against peers. Denali’s 3.3x P/B is below our SWS DCF fair value indication of $32.80 per share, yet above the US Biotechs industry average P/B of 2.7x. The market is therefore assigning it a richer multiple than many sector peers, while our estimate of future cash flows supports a higher share price than today.

Result: Price to book ratio of 3.3x (ABOUT RIGHT)

However, you still need to weigh Denali’s annual net loss of US$512.54 million, as well as the potential dilution from its US$200.73 million shelf registration.

Another Way To Look At Value

That 3.3x P/B might feel about right, but our DCF model comes at it from a different angle. On SWS DCF numbers, Denali at $21.18 is trading below an estimated fair value of $32.80, which frames current pricing as a discount rather than a stretch. So which yardstick do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of risks and potential rewards feels finely balanced, take a closer look now. Shape your own view with 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

Round out your research by lining up a few fresh stock ideas, so you are not relying on a single biotech story to shape your next move.

• Spot potential bargains fast by scanning our list of 47 high quality undervalued stocks that pair solid fundamentals with prices that may still be catching up.
• Explore income-oriented opportunities by checking out 13 dividend fortresses, focused on 5%+ yield names with established payout histories.
• Reduce portfolio volatility by reviewing 76 resilient stocks with low risk scores, which highlights companies with lower risk scores that may help stabilize your overall mix.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.